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Neurodegenerative diseasesOxidative damage contributes to pathogenesis inmany neurodegenerative diseases. As the indicator and regula-
tor of oxidative stress, the Nrf2-ARE pathway has been shown dynamic changes and examined for its neuropro-
tective role in many cases. In this review, we summarize the progress of the Nrf2-ARE pathway in combating
toxicity induced from typicalmisfolded protein aggregates in neurodegenerative diseases, and speciﬁcally the ef-
fects on the clearance of protein aggregates. This article is part of a Special Issue entitled: Misfolded Proteins, Mi-
tochondrial Dysfunction, and Neurodegenerative Diseases.
© 2013 Published by Elsevier B.V.1. Introduction
Maintaining redox homeostasis is imperative for normal function of
the brain. This process is tightly regulated by antioxidants, detoxifying
proteins and other molecules. With age, genetic and environmental
risk factors, the oxidative-redox system becomes imbalanced and oxi-
dative stress ensues through increased levels of reactive oxygen species
(ROS) and reactive nitrogen species (RNS). The rate of ROS/RNS produc-
tion eventually overwhelms our endogenous antioxidant defenses lead-
ing to the accumulation of oxidative damage such as post-translational
modiﬁcations of lipids, proteins and DNA/RNA, a common feature of
many neurodegenerative diseases. The oxidative modiﬁcations affect
the physiological functions of these cell components and cause abnor-
mal deposits in neurons and/or glia in Parkinson's disease (PD),
Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and
Huntington disease (HD). Although it is difﬁcult to distinguish whether
oxidative stress is a cause or effect of the disease because of the multi-
factorial nature of neuronal death and the progressive effects of oxida-
tive stress on cells, the clear association between oxidative damage
and the disease makes therapeutic targeting of the antioxidant systems
an attractive option.olded Proteins, Mitochondrial
isman Center, Molecular and
nce, University of Wisconsin–
hnson).
vier B.V.The nuclear factor erythroid 2-related factor 2 (Nrf2)-antioxidant
response element (ARE) pathway is a primary sensor and a master
regulator of oxidative stress via its ability tomodulate the expression
of hundreds of antioxidant and detoxifying genes [1–3]. Activation of
the Nrf2-ARE pathway has shown beneﬁts in animal models of many
neurodegenerative disorders supporting the concept of developing
pharmaceuticals to activate the Nrf2-ARE pathway in the brain.
This review will summarize the commonality of oxidative damage
in human neurodegenerative diseases and the potential neuropro-
tective effects of the Nrf2-ARE pathway especially against the toxic-
ity from misfolded proteins.
2. Oxidative damage in neurodegenerative diseases
The generation of reactive species can arise through both spontane-
ous and enzymatic reactions. The sources and physiological functions of
reactive species and human disease are explored in other reviews [4,5].
Overall, increased levels of oxidative markers and damaged cell compo-
nents have been observed in the respective disease-affected regions of
patients diagnosed with PD, AD, ALS, and HD. As shown in Table 1,
markers of lipid peroxidation including 4-hydroxynonenol (4-HNE)
are increased in PD [6–8], AD [9–11], ALS [12,13]. 4-HNE modiﬁed
protein adducts have also been observed in the disease-related re-
gions [14–16]. Protein carbonyl reﬂects protein oxidation and can
be generated from direct free radical attack on amino acid side
chains, glycation, and glycoxidation or from lipid oxidation products.
Increased carbonyls have been observed in the substantia nigra (SN)
of PD patients [17,18], and affected brain regions in other diseases
Table 1
Elevated levels of oxidative stress in patients with neurodegenerative diseases.
Lipid peroxidation Oxidized protein Post-translational
modiﬁcation
Oxidized
DNA/RNA
Mitochondria disruption Antioxidants
Parkinson's
disease
MDA↑, HNE↑ [6–8] Carbonyls↑ [17,18] Nitrated, p-αsyn↑, [23,24]
glycosaltaed -αsyn↑ [25]
8-OHDG↑
[30,31]
Complex I ↓ [149,150]
Oxidized CoQ10↑ [151]
mtDNA deletion↑[152]
glutathione↓[40,41]
Alzheimer's
disease
HNE↑, acrole↑ [9–11]
TBARS↑ [153]
HNE pyrrole adducts↑ [14,15],
Carbonyls↑ [19–21]
Nitrotyrosine/dityrosine↑
[28,29]
Nitrated, p-tau ↑ [26,27] 8-OHDG↑
[32,33]
Complex IV activity ↓ [154,155] SOD1 activity↓ catalase↓
[153]
Amyotrophic
lateral sclerosis
HNE↑ [12,13] Hydroxyl
radical↑, ascorbate free
radical↑ [34]
HNE-EAAT2↑ [16]
glycoxidation↑, glycation↑
[36,130]
Carbonyls↑ [22]
Oxidized SOD1↑ [156]
AGEs-SOD1↑ [130]
p-TDP-43 ↑ [131]
8-OHDG↑
[34–36]
Oxidized CoQ10↑ [35]
Complex I activity (cortex)↑,
(lymphocytes)↓ [22,157]
Complex IV activity↓ [158]
mtDNA4977 deletion↑ [159]
SOD/SOD1 protein/
activity↓ [34]
Huntington's
disease
Plasma MDA↑ [37] Carbonyls↑ [72,160]
NADPH
Oxidase↑ [161]
Extended polyQ-Htt [122] 8-OHDG↑
[37,38]
Energy failure [162], calcium↓
[148], mtDNA4977 deletion↑
[163], Complex II/III/IV↓,
aconitase activity↓, citrate
synthase↓ [164,165]
Plasma SOD1, GPX ac-
tivity↓ [37]
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have also been observed in patients, which can affect the structure
and function of proteins. For example, nitrated, phosphorylated and
glycosylated alpha-synuclein (αSyn) has been observed in different re-
gions of patients with synucleinopathies including PD, and dementia
with Lewy bodies (DLB) [23–25]. Nitration and phosphorylation of tau
protein have been found in the hippocampus and neocortex of patients
with AD, Down syndrome and in other tau pathologies [26,27].
Nitrotyrosine and dityrosine cross-linked proteins are elevated 8-fold
and 3-fold, respectively, in hippocampus and neocortical regions of
AD brain compared to age matched controls [28,29]. These disease-
characteristic proteins are also ubiquitinated due to overwhelmed
clearance systems. Besides lipids and proteins, oxidative damage to
DNA/RNA has also increased in both central nervous and peripheral
systems in many patients with different diseases as indicated by the
marker 8-hydroxy-2-deoxyguanosine (8-OHDG) [30–38]. Neverthe-
less, typically the abnormal levels of oxidized and modiﬁed products
correlate with oxidative stress.
It is worth noting that the impaired function of the mitochondrial
electron transport chain is a primary source of oxidative stress. De-
fects in this pathway result in increased free radicals and depleted
ATP levels; both of which have been seen in numerous neurodegen-
erative diseases (Table 1). Increased free radical production can fur-
ther damage mitochondria thereby forming a positive feedback loop.
In addition, free radical levels are increased due to an imbalance be-
tween the rate of oxidant generation and the endogenous antioxi-
dant capacity. Antioxidant systems, many of which are regulated by
the Nrf2-ARE pathway, are responsible for the removal of free radi-
cals. The failure of antioxidant defense systems has also been exam-
ined in postmortem brains of patients with neurodegenerative
diseases. For instance, in accordance with the increased load of reac-
tive species in disease, PD patients have lower reduced glutathione
levels in the SN [39,40] and dopaminergic neurons [41] than in
age-matched controls. This reduction is not evident in the blood
plasma or other parts of the brain [39,42], implicating glutathione
depletion as a secondary feature of increased oxidative stress in the
SN of PD patients. Reduced levels of antioxidants result in further ac-
cumulation of free radicals. Although the animal models of diseases
including genetic and toxin-inducingmodels may not totally recapit-
ulate all the symptoms of human patients, similar changes in oxida-
tive damage have been observed in many of animal models [43–46].
As activation of the Nrf2-ARE pathway can boost the ability to buffer
free radical generation, it provides a valuable therapeutic target for
the treatment of neurodegenerative diseases.3. The Nrf2-ARE pathway and neuroprotection
3.1. The Nrf2-ARE pathway
Nrf2 is ubiquitously expressed in all human tissues including the
brain, and is one of the cap'n'collar (CNC) transcription factors [47].
CNC proteins are a family of basic leucine zipper transcription factors
that are conserved in vertebrates. They are deﬁned by the presence
of a conserved 43-amino acid CNC motif, which is located in the N-
terminal of the DNA binding domain [48]. The ARE is an enhancer el-
ement with the consensus sequence RTGACnnnGC, located in the 5′
ﬂanking region of many phase II detoxifying and antioxidant genes
[49,50]. Nrf2 binds to the ARE through its DNA binding domain to
regulate this pathway [47]. Under basal conditions, Nrf2 is negatively
regulated in the cytoplasm by kelch-like ECH associating protein 1
(Keap1). Keap1 prevents the nuclear translocation of Nrf2 and func-
tions as an adaptor protein to E3 ligase to promote the degradation of
Nrf2 via the ubiquitin proteasome system (UPS) [51–56]. Upon
disruption of Keap1-Nrf2 binding, Nrf2 translocates to the nucleus
and binds with small Maf proteins. The formed heterodimer binds
to the ARE and coordinates the transcription of genes involved in
phase II detoxiﬁcation and antioxidant defense [57]. Proteins
expressed by these phase II detoxifying and antioxidant genes are re-
sponsible for maintaining redox balance. Some examples include su-
peroxide dismutase 1 (SOD1), catalase, sulforedoxin, thioredoxin,
and peroxiredoxin. Other proteins involved in glutathione synthesis
and metabolism include glutathione peroxidase, glutathione reduc-
tase, gamma glutamine cysteine ligase, and gamma glutamine cyste-
ine synthase. Additionally, there are proteins that prevent quinone
recycling, and preserve iron homeostasis based onmicroarray analy-
sis following Nrf2 activation [2,3,58].
3.2. Dynamic changes of the Nrf2-ARE pathway in neurodegenerative
diseases
Dynamic changes are seen in the Nrf2-ARE pathway in patients and
animal models of aging and disease demonstrating the accumulation of
oxidative damage and the importance of this pathway in combating ox-
idative stress. Studies have established that Nrf2 nuclear translocation is
induced in dopaminergic neurons in human PD cases, but is diminished
in hippocampus neurons in AD cases [59]. mRNA and protein levels of
Nrf2 are reduced in the motor cortex and spinal cord in ALS patients,
and mRNA level of Keap1 is increased in the motor cortex [60]. Nrf2-
dependent downstream genes have also been examined in postmortem
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ulated by Nrf2 such as SOD1 and catalase are reduced in patients
(Table 1). Meanwhile, there are publications reporting upregulation of
other Nrf2-dependent genes as discussed below. NAD(P)H:quinone ox-
idoreductase 1 (NQO1), an antioxidant enzyme catalyzing the two-
electron reduction of quinones via NADH or NADPH, is upregulated in
astrocytes, neurons and other cell types in human PD [61] and AD
brain [62–64]. A similar pattern is observed with heme oxygenase 1
(HO-1) found in reactive astrocytes and neurons in the brain of
human PD [65,66] and AD patients [67]. HO-1 catalyzes the degradation
of heme to biliverdin, which is then degraded to bilirubin. Both biliver-
din and bilirubin have antioxidant properties [68,69]. Peroxiredoxin, a
thioredoxin dependent peroxidase that reduces hydrogen peroxide, is
also upregulated in PD [70] and AD [71]. An oxidative stress analysis
based on proteomic data reveals that antioxidant proteins including
peroxiredoxins, glutathione peroxidases (GPX), SOD2 and catalase are
induced in the striatum of HD patients [72]. However, it is currently
impossible to track the status of the Nrf2-ARE pathway during the pro-
gression of the disease because the data have been collected from post-
mortem brain tissue. Therefore, it is unclear whether the observed
upregulation of Nrf2-ARE controlled proteins and Nrf2 nuclear translo-
cation is a persistent feature of patients or a compensatory end-stage
process in these diseases.
In order to clarify these questions, studies on the perturbation of the
Nrf2 pathway have been done using cell models from patients. Take PD
as an example, pluripotent stem cells (iPSC)-derived neurons, which are
generated from skin ﬁbroblasts from PD patients carrying PARK2muta-
tions, show increased oxidative stress, dysfunctional mitochondria and
enhanced activity of the Nrf2 pathway [73]. Another study proﬁling
the gene expression of neurospheres obtained from the olfactorymuco-
sa of PD patients and non-PD controls indicates that there is a signiﬁcant
dysregulation of the Nrf2-ARE pathway in PD patient cells relative to
control patient cells [74]. These results suggest that the proﬁle of Nrf2-
ARE activation changes throughout the course of disease.Fig. 1. Dynamic changes of Nrf2-ARE pathway in different ages of hαSynA53T transgenic mic
nonsymptomatic hαSynA53T mice and sympmatic hαSynA53T mice (6–8 month old). n = 4. #p
in spinal cord of 2- and 6-month-old nonsymptomatic hαSynA53T and 6-month-old sympmat
hαSynA53T(−), *p b 0.01, 6-month old hαSynA53T (+) versus 2-month old hαSynA53T(−).Similar changes are observed in animal models of PD. As shown in
Fig. 1, the Nrf2-ARE pathway undergoes dynamic changes with the
disease progression in the spinal cord in a αSyn mutant A53T trans-
genic mouse model of PD (hαSynA53T) [44]. Speciﬁcally, Nrf2 down-
stream genes related to glutathione synthesis increase at the early
stage and decrease at the late stage disease with corresponding
change in the total glutathione levels (Fig. 1A and B). Other genes
such as GSTA4 and NQO1 have a similar trend, whereas Nrf2 itself in-
creases at the late stage of the disease indicating the possibility of a
compensatory response to the reduced glutathione and Nrf2-
dependent gene levels. In another genetic αSyn mouse model driven
by the tyrosine hydroxylase (TH) promoter, Nrf2 regulated genes in-
cluding those involved in glutathione synthesis, metabolism and trans-
portation and detoxiﬁcation of hydrogen peroxide/quinones increase in
the SN and striatum of 1-month-old αSyn mice [75]. However, these
genes in the SN return to normal levels in 6- and 12-month old mice,
whereas they continue to be upregulated until 6 month in the striatum.
There is also upregulation of Nrf2-dependent genes in the SN but not in
the striatum in a subchronic MPTP mouse model [76]. The Nrf2-ARE
system is activated in cell culture systems as well in response to para-
quat and maneb [77], and 6-hydroxydopamine [77,78].
Apparently, the extent of endogenous activation of the Nrf2-ARE
pathway is insufﬁcient to combat the overload of oxidative stress due
to eventualmortality. Thus, the search for exogenousmeans to enhance
the endogenous Nrf2-ARE activation has the potential to help the brain
defend itself from oxidative damage. Proof-in-principle as to the beneﬁt
of this approach has been demonstrated in multiple animal models of
neurodegenerative diseases [44,79–82].
3.3. Misfolded proteins in neurodegenerative diseases and neuroprotection
of Nrf2-ARE pathway
Misfolded proteins and subsequent aggregate/inclusion formation
are important contributors to pathology in many neurodegenerativee. A, mRNA levels of Nrf2 and its regulated genes in spinal cord of 2- and 6-month-old
b 0.01, *p b 0.001, hαSynA53T(+) versus age-matched hαSynA53T(−). B, Total GSH levels
ic hαSynA53T mice. n = 3–5. #p b 0.05, 2-month old hαSynA53T (+) versus age-matched
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gates such asαSyn in PD, beta-amyloid plaques (Aβ) and tau neuroﬁla-
ment tangles (NFTs) in AD, and Huntingtin (Htt) in Huntington's
disease. Oxidative stress is a main source of protein modiﬁcations, and
it affects their synthesis, folding and function. These post-translational
modiﬁcations also cause organelle dysfunction. The Nrf2-ARE pathway
modulates oxidative stress and thus protects against protein oxidation.
This section will focus on neuroprotection via the Nrf2-ARE pathway in
neurodegenerative diseases with an emphasis on misfolded proteins.
3.3.1. Nrf2-ARE pathway and Parkinson's disease
PD is themost common neurodegenerativemovement disorder. The
loss of dopaminergic neurons in SN causes a reduction of dopamine in
the terminals in striatum. Intracellular inclusions [Lewy bodies (LBs)]
are a hallmark of PD, and have been found in both familial and sporadic
PD patients with αSyn as the main component of LB and Lewy neuritis
[83,84]. Multiplication and three missense mutations (A53T, A30P,
E64K) of αSyn gene have been associated with autosomal dominant
PD [85–87]. αSyn is a small protein with 140 amino acids that is
enriched in presynaptic nerve terminals, strongly suggesting a role in
synaptic transmission [88].αSyn has been reported to adjust dopamine
levels through affecting TH phosphorylation and activity, and the
amount of dopamine transporter on cell membrane [89–91]. It also
bindswith complex I and affectsmitochondria function [92].αSyn is na-
tively unfolded and is prone to form ﬁbrils under disease condition.
Postranslational modiﬁcations, especially phosphorylated- (p-) and/or
nitrated-αSyn positive-aggregates are present in areas of the central
nervous system associated with pathology in early and late stages of
PD patients [23,93,94]. Nitrated-, oxidized-, and 4-HNE-αSyn has been
shown to promote oligomerization and prevent ﬁbrilization in vitro. In
particular, 4-HNE-αSyn induced toxic oligomers can be taken up by
neuronal cells and function as seeds to accelerate the amyloidogenesis
of monomeric αSyn. This is reﬂected by the studies that the treatment
with 4-HNE increased the cell-to-cell transfer of αSyn protein [95–97].
Furthermore, oxidized-αSyn is more prone to form toxic aggregates
and it has been reported that oxidized glutathione stimulates the amy-
loid formation of αSyn [98]. These data indicate that oxidative stress
plays an important role in αSyn proteostasis. As the master regulator
of the cellular antioxidant defense system, the Nrf2-ARE pathway is a
logical target to examine for neuroprotection againstmisfolded proteins
induced pathology.
Activation of theNrf2-ARE pathway has been shown to be protective
against the toxic forms of αSyn in several studies. In SK-N-SH neuro-
blastoma cells, ferrous iron promotes αSyn aggregation through
inhibiting Nrf2 pathway [99]. αSyn aggregation exacerbates ferrous
iron-induced oxidative damage,mitochondrial impairment and apopto-
sis. Overexpression of Nrf2 downstreamgeneHO-1 is able to reverse the
toxicity. In a Drosophilamodel of PDwithαSyn, it was found that trans-
genic activation of Nrf2 by overexpression of Nrf2 or Maf-S and knock-
down of Keap1 could delay the αSyn-mediated dopaminergic neuron
loss and motor dysfunction [100]. Correspondingly, genetic deletion of
Nrf2 enhances αSyn toxicity delivered via an adeno-associated viral
vector and exaggerates αSyn/p-αSyn accumulation in dopaminergic
neurites and gliosis in vivo [101]. αSyn treatment activates the Nrf2
and NF-κB pathway and promotes proinﬂammatory cytokine produc-
tion, as well as phagocytosis in vitro. Nrf2 deﬁciency enhances the in-
ﬂammatory response and lowers the capability of phagocytosis in
primary microglial cells. The authors speculate that the Nrf2 pathway
may be involved in αSyn degradation through the UPS seeing that the
basal mRNA levels of proteasome subunits PSMB7, PSMC3 and PSMC4
are slightly lower in the ventral midbrain of Nrf2 KO mice compared
with Nrf2 WT mice, and PSMB7 only increases in Nrf2 WT mice, not in
Nrf2 KO mice, after overexpression of αSyn [101].
Recently, our laboratory has identiﬁed the importance of astro-
cytic Nrf2 regulating αSyn proteostasis. Astrocytic overexpression
of Nrf2 (GFAP-Nrf2) can reduce αSyn aggregates in the centralnervous system of a PD mouse model with neuronal overexpression
of human αSyn mutant A53T (Thy1-hαSynA53T) (as shown in Figs. 2
and 3) [44]. These observations are not due to Nrf2-mediated down-
regulation of the hαSynA53T transgene levels in the mice (Fig. 2A).
The amount of hαSynA53T in the Triton-soluble fraction from the spi-
nal cord decreases 60% in symptomaticmice [AN(+/−)*] (Fig. 2B, C).
This is accompanied by a signiﬁcant increase in hαSynA53T in the
Triton-insoluble/SDS-soluble fraction. This movement of αSynA53T
into Triton-insoluble/SDS-soluble aggregates is completely reversed
by overexpression of Nrf2 in astrocytes [AN(+/+)] (Fig. 2B, C).
Similar changes are observed for phosphorylated (Ser129) αSynA53T
(p-hαSynA53T) in Triton soluble and Triton-insoluble/SDS-soluble
fractions (Fig. 2B). Fluorescent staining of hαSynA53T also shows a
dramatic increase in hαSynA53T aggregates that colocalized with p-
hαSynA53T (Fig. 2D, E). Again, these changes are completely reversed
by GFAP-Nrf2 [AN(+/+)] (Fig. 2D).
In addition, immunostaining shows increased density of p-hαSynA53T
in the motor cortex, middle brain, and brain stem in symptomatic
hαSynA53T mice (Fig. 3A, B). There is a striking increase of p-hαSynA53T
staining in SN, especially in the pars reticulata (SNpr) (Fig. 3B middle
panel). The GFAP-Nrf2 mice completely prevented or signiﬁcantly re-
duced the p-hαSynA53T accumulation throughout these different brain
regions (Fig. 3A, B).
The autophagy-lysosome pathway (ALP) is a highly conserved
bulk protein degradation system responsible for the turnover of
long-lived proteins, clearance of aggregate-prone proteins and dis-
posal of damaged organelles. Inactivation of autophagy results in cy-
toplasmic protein inclusions composed of misfolded proteins and
deformed organelles, leading to neurodegeneration and other diseases
[102–104]. There is signiﬁcant autophagic dysfunction observed in the
αSynA53T mice with reduced macroautophagy as well as chaperone-
mediated autophagy [44,105–107]. Indeed, the increased lifespan, de-
layed onset and reduced aggregation in αSynA53T mice are due to the
GFAP-Nrf2-mediated prevention of macroautophagy and chaperone-
mediated autophagy dysfunction in the αSynA53T transgenic mice [44].
3.3.2. Nrf2-ARE and Alzheimer's disease
AD is the most common progressive neurodegenerative disorder
leading to the development of dementia and eventually death. It is
characterized by degeneration of synapses and loss of neurons in
the hippocampus and neocortex. The neuropathological hallmarks
of this disease are extracellular senile plaques (SPs) and intracellular
neuroﬁbrillary tangles (NFTs). NFTs are composed of the microtubule-
associated protein tau, which is hyperphosphorylated as well as oxida-
tively modiﬁed. SP is mainly composed of a small peptide Aβ (4 kDa),
which is derived proteolytically from the beta-amyloid precursor pro-
tein (APP) [108–110].
A number of studies have shown that activation of Nrf2 can atten-
uate the toxicity mediated by Aβ. However, most studies focus on the
neuroprotection by the Nrf2-ARE pathway against ROS generation
and cell death induced by Aβ in vitro [111–114]. Unfortunately, the
effects of the Nrf2 pathway on Aβ processing, clearance and aggrega-
tion in vivo is controversial. Terbutylhydroquinone (tBHQ), a proto-
typical Nrf2 activator, has been reported to reduce toxin-induced
Aβ1-42 secretion in the NT2N cell line with increased cell viability
[115]. However, it is difﬁcult tomake the conclusion that Nrf2 activa-
tion reduces the formation of Aβ aggregates or just simply prevents
the release of monomer/oligomeric Aβ from dead cells. Another
Nrf2 activator sulforaphane improves cognitive function in an acute
mouse model of AD without shifting Aβ solubility [116]. Strikingly,
overexpression of mitochondria catalase, one of the downstream
genes regulated by Nrf2-ARE pathway, in APP (Tg2576) transgenic
mice dramatically reduces full length APP and it's c-terminal frag-
ment 99, lowers soluble and insoluble Aβ levels, extends lifespan
and improves working memory [43]. A genetic approach through
lentivirus-assisted overexpression of Nrf2 in the hippocampus of
Fig. 2.Overexpression of Nrf2 in astrocytes decreases hαSynA53T and p-hαSynA53T aggregates in spinal cord. A,Western blotting of hαSynA53T for Triton-soluble fractions from spinal cords
of 2-month-old hαSynA53T mice and age-matched littermates. Quantiﬁcation is shown in the right, mean ±SEM; n = 4. B, Western blotting of hαSynA53T and p-hαSynA53T in Triton-
soluble and -insoluble fractions (SDS-soluble fractions) from the spinal cord of 6-month-old hαSynA53T mice and age-matched littermates. C, Quantiﬁcative data for hαSynA53T protein
level, mean ±SEM; n = 3. *p b 0.001, AN(+/−)* versus AN(−/−); #p b 0.001, AN(+/+) versus AN(+/−)*; +p b 0.05, AN(+/+) versus AN(+/−). D–E, Fluorescent immunostaining
of hαSynA53T and p-hαSynA53T aggregates with 80% formic acid pretreatment in spinal cord of 6-month-old mice. D, Staining for hαSynA53T in asymptomatic, symptomatic, and double
transgenic mice. E, Colocalization of hαSynA53T and p-hαSynA53T in symptomatic mice; n = 3. Scale bars: 50 μm. Modiﬁed from Gan et al. [44].
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fraction without affecting the total Aβ burden, accompanied with im-
proved spatial learning memory measured by the Morris Water Maze
[117]. This agrees with the concept that soluble oligomer Aβ is thetoxic form as opposed to the plaques [118,119]. A study from our labo-
ratory suggests that APP/PS1 mice on an Nrf2 knockout background
show an increased accumulation of insoluble APP fragments and Aβ
(Joshi et al., manuscript submitted). This observation along with an
Fig. 3.Overexpression of Nrf2 in astrocytes decreases p-hαSynA53T aggregates in the brain. Representative ﬂuorescent immunoimages of p-hαSynA53T [148] with 80% formic acid
pretreatment in different brain areas of 6-month-old asymptomatic, symptomatic, and double transgenic mice. A, Middle Brain (MB) and brainstem (BS). Scale bar, 1000 μm.
Higher magniﬁcation images of the oval and square areas are shown in B, middle and bottom, respectively. MCX, motor cortex. Blue: Hoechst; n = 3. Scale bar, 50 μm. Modiﬁed
from Gan et al. [44]. Captions: AN(−/−): hαSynA53T(−)/GFAP-Nrf2(−) mice; AN(+/−): nonsymptomatic hαSynA53T(+)/GFAP-Nrf2(−) mice; AN(+/−)*: symptomatic
hαSynA53T(+)/GFAP-Nrf2(−) mice; AN(+/+): hαSynA53T(+)/GFAP-Nrf2(+) mice; AN(−/+): hαSynA53T(−)/GFAP-Nrf2(+) mice.
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1214 L. Gan, J.A. Johnson / Biochimica et Biophysica Acta 1842 (2014) 1208–1218increase in mTOR activity suggests that Nrf2 could mediate autophagy
and alter processing/clearance of APP and/or Aβ.
3.3.3. Nrf2-ARE and Huntington's disease
HD is a neurodegenerative disease of genetic origin with an auto-
somal dominant inheritance pattern. The neuropathological charac-
terization of the disease is the loss of medium-sized spiny neurons
in the striatum.With disease progression, neuropathology is also ob-
served in other brain regions including the cerebral cortex, the
globus pallidus, the thalamus, and the cerebellum. The HD gene
(huntingtin) was identiﬁed in 1993 and has an abnormal expansion
of cytosine, adenine, and guanine (CAG) trinucleotide repeats
[120,121]. The number of pathogenic CAG repeats correlates with
the severity and age of onset of the disease. The abnormal CAG ex-
pansion results in the expression of an unusually long N-terminal
poly-glutamine (polyQ) stretch in the huntingtin protein (Htt)
[122]. N-terminal fragments of the mutant Htt (mHtt) proteins con-
taining the polyQ repeat are aggregation-prone and form intracellu-
lar inclusion bodies.
Our lab and others have shown that activation of the Nrf2-ARE
pathway can protect against toxicity from mHtt [79,81,123]. Nrf2
signaling is severely compromised by the presence of mHtt in the
striatal cell line STHdhQ111/Q111 compared towildtype (wt)Htt express-
ing cell line STHdhQ7/Q7 [124]. STHdhQ111/Q111 cells fail to activate Nrf2
in response to oxidative stress and activators. The investigators reason
that this impaired Nrf2 pathway may be partially due to activated au-
tophagy pathway because mRNA and protein levels Nrf2 itself are not
changed but protein levels of Nrf2 modulators, Keap1 and p62, are
reduced. Keap1 and p62 are substrates of autophagy [125,126], and re-
duction of Keap1 and/or induction of p62 are known to activate theNrf2
pathway [127]. In view of this, the exact cause requires further investi-
gation. Nevertheless, coexpression of Nrf2 attenuates the fragmentation
of mitochondria in STHdhQ111/Q111 cells. A microarray analysis shows
that there is an induction of the Nrf2-ARE pathway in an inducible rat
PC12 cell line expressing an exon 1 fragment of huntingtin with Q74
glutamine repeats [128]. Following 5 days of doxycycline-mediated
induction there are extensive aggregation as well as increases in de-
toxifying and antioxidant genes including NQO1, GSTA4, GSTP2, cat-
alase, SOD1, SOD2, metallothionein 3, glutathione peroxidase and
glutathione biosynthesis genes including GCLm, GCLc. These in-
creases are not seen in cells expressing Q23 glutamine repeats or
after 1-day doxycycline induction. These results indicate that activa-
tion of the Nrf2-ARE pathway is a compensatory response and the
cells attempt to prevent the oxidative stress induced by aggregate
formation. Although direct evidence of Nrf2 modulating Htt aggre-
gates remains elusive, cotransfection of Nrf2 with mHtt in primary
striatal neurons shortens the mean lifetime of mHtt N-terminal frag-
ments and improves cell viability [129]. This strongly suggests that
Nrf2 has the potential to alter mHtt levels thereby altering the extent
of aggregation.
3.3.4. Nrf2-ARE and amyotrophic lateral sclerosis
ALS is a progressive fatal disease caused by degeneration of lower
motor neurons in the ventral horn of the spinal cord and the upper
motor neurons of the motor cortex, resulting in progressive motor
weakness. Ubiquitinated aggregates are present in patient brains.
For almost 15 years, the only gene clearly associated with familiar
ALS was the Cu–Zn superoxide dismutase 1 (SOD1). Advanced
glycation endproduct-modiﬁed SOD1-positive inclusions are com-
mon to familial ALS patients with SOD1 gene mutations and trans-
genic mice expressing human SOD1 with a G85R mutation [130].
SOD1 aggregates are not usually detected in sporadic cases. Recently,
RNA/DNA-binding proteins, 43-kDa transactive response (TAR)
DNA-binding protein (TDP-43) and fused in sarcoma/translocated
in liposarcoma (FUS/TLS) were identiﬁed to associate with sporadic
and non-SOD1 familial ALS [131–135]. Both TDP-43 and FUS arepredominantly nuclear proteins involved in diverse aspects of RNA
metabolism, however, both are observed as aggregates in the cytosol
of affected neurons in ALS disease. This ﬁnding suggests that aber-
rant neuronal cytoplasmic protein aggregation and defective RNA
metabolism appear to be common pathogenic mechanisms involved
in ALS and possibly in other neurodegenerative disorders. Interest-
ingly, both TDP-43 and FUS contain “glycine-rich” domains and
most of the disease-related mutations occur in this region [136].
Nrf2 activators have been shown to protect against oxidative
stress and cell death induced by SOD1 mutant protein [137,138]. As-
trocytic expression of Nrf2 extends lifespan and enhances motor
neuron survival in the spinal cord of SODG93A and SODH46R/H48Q
transgenic mouse model of ALS [82]. Cocultures of motor neurons
derived from wild-type mice and astrocytes derived from SODG93A
mice lead to motor neuron death. Overexpression of Nrf2 in the
SODG93A astrocytes is sufﬁcient tomitigate the toxicity. Interestingly,
speciﬁc overexpression of Nrf2 in neurons or muscle does not affect
the lifespan in SODG93A and SODG85R mice, and genetic deletion of
Nrf2 has no impact on the disease progression and pathology of
SODG93A mice [139–141].
Recently, NSC34 motor neuronal cell lines expressing TDP-43
mutants exhibit shortened neurites, increased oxidative stress and
decreased HO-1 level. These effects are reversed by the UPS inhibi-
tor MG132, but not by the Nrf2 activator sulforaphane [142,143].
This is attributed to an increase in HO-1 followingMG132 treatment
that appeared to be independent of Nrf2 activation. The question as
to how mutant TDP-43 reduces expression of HO-1 and prevents
sulforaphane from activating Nrf2 signaling remains to be deter-
mined. While the role of Nrf2 in protection against SOD1 mutant
neuronal toxicity is clear, its effect on other ALS-associated gene
mutations particularly TDP43 and FUS needs to be clariﬁed by fu-
ture studies.4. Conclusions
Oxidative stress and misfolded proteins act synergistically to
contribute to the pathogenesis of multiple neurodegenerative dis-
eases. Oxidative modiﬁcation of proteins can affect protein structure
and biological functions. In many diseases, proteins with abnormal
modiﬁcations have increased potential to form aggregates. In addi-
tion, misfolded proteins sequester other proteins into the forming
aggregates, cause functional failure of organelles, and enhanced oxi-
dative stress. Neuroprotection by the Nrf2-ARE pathway against ox-
idative damage and cell death has been the primary focus of research
surrounding Nrf2 for many years. However, gathering evidence sup-
ports the concept that the Nrf2-ARE pathway may modulate the
formation and degradation of misfolded protein aggregates in neuro-
degenerative diseases. The detailed mechanism as to how activation
of the Nrf2-ARE pathway alters cellular proteostasis is still obscure. Is
it by decreasing the overload of oxidative stress? Is it due to some as
of yet unidentiﬁed downstream pathway regulated via Nrf2? Or is it
a combination of both concepts? Current data suggest that Nrf2
affects both primary protein degradation pathways, the UPS and ALP,
which are both altered in neurodegenerative diseases [144–147].
Since the research progression sheds light on the importance of the
Nrf2-ARE pathway in the clearance of misfolded protein aggregates,
more efforts should be put forth in elucidating how Nrf2 could
maintain/enhance proteostasis so that it may lead to discovery of
new targets for the treatment of neurodegenerative diseases.Acknowledgements
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